Ratings Zhaoke Ophthalmology Limited

Equities

6622

KYG989M51017

Market Closed - Hong Kong S.E. Other stock markets 09:08:12 14/06/2024 BST			5-day change	1st Jan Change
1.4 ^HKD	-1.41%		-4.76%	-64.56%

04-29	Zhaoke Ophthalmology Shrinks Loss in 2023	MT
04-08	Zhaoke Ophthalmology Limited Announces the Resignation of Chen Yu Has as Non-Executive Director	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Thanks to a sound financial situation, the firm has significant leeway for investment.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Analyst opinion has improved significantly over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ZHAOKE OPHTHALMOLOGY LIMITED	-64.56%	97.88M	-
ELI LILLY AND COMPANY	+50.70%	791B	C+
NOVO NORDISK A/S	+41.96%	630B	B
JOHNSON & JOHNSON	-7.15%	350B	C+
MERCK & CO., INC.	+18.77%	328B	B-
ABBVIE INC.	+8.79%	298B	C+
ASTRAZENECA PLC	+18.02%	246B	B+
ROCHE HOLDING AG	+1.27%	225B	A+
NOVARTIS AG	+11.95%	218B	B-
AMGEN INC.	+3.68%	160B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes